Polaryx Therapeutics Stock
Polaryx Therapeutics, Inc. Common Stock
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Alex Yang
- Employees
- 11
- Market cap
- $94 M
- IPO
- 02/02/2026
- Web
- polaryx.com
Polaryx Therapeutics, Inc. functions as a biotechnology firm dedicated to advancing small-molecule therapies for lysosomal storage and neurodegenerative conditions. Its developmental pipeline includes a trio of promising candidates: PLX-100, which combines PLX-200 with an ancillary supplement, targeting late infantile…
Polaryx Therapeutics stock: price history
1D
-3.6%
1W
-6.0%
1M
-7.4%
6M
-69.3%
YTD
–
1Y
–
2Y
–
5Y
–
10Y
–
Next earnings date
Next earnings date
No date known
Volatility around earnings
~27% stronger price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vsqueeze-release-v1.0 on 13/10/26. Not a buy or sell signal.Beta
What does this mean?
Volatility squeeze
BearishPrice swings had compressed unusually tight beforehand (volatility near a low) and are now releasing into a stronger move. Technical analysis views such tight phases as often preceding a bigger move.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Ask the agents about Polaryx Therapeutics
Analyst assessment of Polaryx Therapeutics
PRICE TARGET LOW
US$6.00
CONSENSUS
US$6.50
MEDIAN
US$6.50
PRICE TARGET HIGH
US$7.00
No current analyst ratings available.
Polaryx Therapeutics stock metrics
P/E
-15.45
P/B
8.3
EV/EBITDA
-12
RETURN ON EQUITY
-12.6%
NET MARGIN
0.0%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
46.5%
FLOAT SHARES
23,167,603
AVG. DAILY VOLUME (30D)
30,877
Insider transactions (SEC)
Yang Alex Keun Mo
Institutional holders
Comparable stocks
Frequently asked questions about Polaryx Therapeutics stock
What does Polaryx Therapeutics do?
Polaryx Therapeutics, Inc. Common Stock is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Alex Yang, the company employs around 11 people.
The IPO was on 02/02/2026; the stock trades on NASDAQ under the ticker PLYX.
What do analysts say about Polaryx Therapeutics stock?
The average price target is US$6.50, ranging from US$6.00 to US$7.00, with a median of US$6.50.
This is an external assessment, not a statement by Market Jury.
When does Polaryx Therapeutics report next?
Around past earnings, price swings were roughly 27% stronger than usual.
Does Polaryx Therapeutics pay a dividend?
No, Polaryx Therapeutics currently does not pay a dividend.
Which stocks are comparable to Polaryx Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Polaryx Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Polaryx Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.